{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:13:08Z","timestamp":1790007188186,"version":"4.0.1"},"reference-count":41,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>GH deficiency (GHD) is common among childhood cancer survivors (CCSs) with history of tumors, surgery, and\/or radiotherapy involving the hypothalamus-pituitary region. We aimed to evaluate the effects of GH therapy (GHT) in CCSs on adult height, risk of diabetes mellitus, abnormal lipids, metabolic syndrome, quality of life, secondary tumors, and disease recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched multiple databases for randomized and observational studies. Pairs of reviewers independently selected studies and collected data. Random effects meta-analysis was used to pool outcomes across the studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 29 observational studies at moderate to high risk of bias. Sixteen studies compared CCSs on GHT with those not on GHT (512 patients, GH dose: 0.3 to 0.9 IU\/kg\/week). GHT was significantly associated with height gain [standard deviation score, 0.61; 95% CI, 0.08 to 1.13] and was not significantly associated with the occurrence of secondary tumors [odds ratio (OR), 1.10; 95% CI, 0.72 to 1.67] or tumor recurrence (OR, 0.57; 95% CI, 0.31 to 1.02). Thirteen studies compared CCSs on GHT with normal age- or sex-matched controls or controls with idiopathic GHD or short stature. GHT was associated with either improved or unchanged risk of diabetes, lipid profiles, and metabolic syndrome. GHT was associated with improvements in quality of life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CCSs treated with GHT gain height compared with the untreated controls. GHT may improve lipid profiles and quality of life and does not appear to increase the risk of diabetes or the development of secondary tumors, although close monitoring for such complications remains warranted due to uncertainty in the current evidence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2018-01205","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T18:08:17Z","timestamp":1530295697000},"page":"2794-2801","source":"Crossref","is-referenced-by-count":57,"title":["GH Therapy in Childhood Cancer Survivors: A Systematic Review and Meta-Analysis"],"prefix":"10.1210","volume":"103","author":[{"given":"Shrikant","family":"Tamhane","sequence":"first","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Endocrinology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad G","family":"Sfeir","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Endocrinology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana Esi N","family":"Kittah","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Jasim","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Chemaitilly","sequence":"additional","affiliation":[{"name":"Department of Pediatric Medicine, Division of Endocrinology, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie E","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Hassan","family":"Murad","sequence":"additional","affiliation":[{"name":"Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"issue":"1","key":"2020071623270560900_B1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bmt.1705694","article-title":"Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation","volume":"40","author":"Chemaitilly","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2020071623270560900_B2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/EJE-12-1083","article-title":"Fifteen years of GH replacement improves body composition and cardiovascular risk factors","volume":"168","author":"Elbornsson","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2020071623270560900_B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-16-0875","article-title":"Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency","volume":"176","author":"Elbornsson","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2020071623270560900_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-28038-7","volume-title":"Growth Hormone Deficiency","author":"Cohen","year":"2016"},{"issue":"7","key":"2020071623270560900_B5","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2020071623270560900_B6","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 10 September 2017."},{"issue":"3","key":"2020071623270560900_B7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.mayocp.2017.01.001","article-title":"Clinical practice guidelines: a primer on development and dissemination","volume":"92","author":"Murad","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2020071623270560900_B8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"6","key":"2020071623270560900_B9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000452150","article-title":"Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"2020071623270560900_B10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-09-0690","article-title":"Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience","volume":"162","author":"Beckers","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2020071623270560900_B11","first-page":"28","article-title":"Final height in children with medulloblastoma treated with growth hormone","volume":"64","author":"Ranke","year":"2005","journal-title":"Horm Res"},{"issue":"8","key":"2020071623270560900_B12","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1210\/jc.2003-030366","article-title":"Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement","volume":"88","author":"Gleeson","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2020071623270560900_B13","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1210\/jc.2004-0160","article-title":"Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study","volume":"89","author":"Brownstein","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2020071623270560900_B14","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1210\/jc.2003-030619","article-title":"Adult height and adult sitting height in childhood medulloblastoma survivors","volume":"88","author":"Xu","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1-2","key":"2020071623270560900_B15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000180073","article-title":"Final stature in brain tumours other than craniopharyngioma: effect of growth hormone","volume":"22","author":"Herber","year":"1985","journal-title":"Horm Res"},{"issue":"4","key":"2020071623270560900_B16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1651-2227.1989.tb17937.x","article-title":"Improved growth response to GH treatment in irradiated children","volume":"78","author":"Lannering","year":"1989","journal-title":"Acta Paediatr Scand"},{"issue":"1","key":"2020071623270560900_B17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/JPEM.1997.10.1.41","article-title":"Growth hormone treatment in irradiated children with brain tumors","volume":"10","author":"Corrias","year":"1997","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"2020071623270560900_B18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0936-6555(05)80744-7","article-title":"The evolution of spinal growth after irradiation","volume":"3","author":"Clayton","year":"1991","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"2020071623270560900_B19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000184276","article-title":"Efficacy of growth hormone replacement therapy in children with organic growth hormone deficiency after cranial irradiation","volume":"43","author":"Vassilopoulou-Sellin","year":"1995","journal-title":"Horm Res"},{"issue":"4","key":"2020071623270560900_B20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000284393","article-title":"Effectiveness of rhGH treatment on adult height in GH-deficient childhood survivors of medulloblastoma","volume":"73","author":"Ciaccio","year":"2010","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2020071623270560900_B21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1210\/jcem.87.1.8146","article-title":"GH-deficient survivors of childhood cancer: GH replacement during adult life","volume":"87","author":"Murray","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2020071623270560900_B22","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1210\/jc.2010-0117","article-title":"Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia","volume":"95","author":"Follin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071623270560900_B23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1210\/jc.2004-0832","article-title":"The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy","volume":"90","author":"Mukherjee","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2020071623270560900_B24","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jc.2011-0112","article-title":"Long-term safety of growth hormone replacement after CNS irradiation","volume":"96","author":"Mackenzie","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2020071623270560900_B25","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1210\/jc.2006-0656","article-title":"Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor","volume":"91","author":"Ergun-Longmire","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2020071623270560900_B26","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1210\/jcem.87.7.8606","article-title":"Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study","volume":"87","author":"Sklar","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071623270560900_B27","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1210\/jc.2013-4159","article-title":"Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study","volume":"99","author":"Patterson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2020071623270560900_B28","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2015-1002","article-title":"Risk of neoplasia in pediatric patients receiving growth hormone therapy--a report from the Pediatric Endocrine Society Drug and Therapeutics Committee","volume":"100","author":"Raman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2020071623270560900_B29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archpedi.1985.02140060029020","article-title":"Growth hormone therapy and tumor recurrence. Findings in children with brain neoplasms and hypopituitarism","volume":"139","author":"Arslanian","year":"1985","journal-title":"Am J Dis Child"},{"issue":"6842","key":"2020071623270560900_B30","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1136\/bmj.304.6842.1601","article-title":"Growth hormone and tumour recurrence","volume":"304","author":"Ogilvy-Stuart","year":"1992","journal-title":"BMJ"},{"issue":"10","key":"2020071623270560900_B31","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1080\/08035250600577889","article-title":"Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database)","volume":"95","author":"Darendeliler","year":"2006","journal-title":"Acta Paediatr"},{"issue":"2","key":"2020071623270560900_B32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.2001.19.2.480","article-title":"Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control","volume":"19","author":"Packer","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020071623270560900_B33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-14-1123","article-title":"Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study","volume":"172","author":"Child","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"13","key":"2020071623270560900_B34","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2002.09.142","article-title":"Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia","volume":"20","author":"Leung","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020071623270560900_B35","first-page":"4444","article-title":"Growth hormone treatment of children with brain tumors and risk of tumor recurrence","volume":"85","author":"Swerdlow","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2020071623270560900_B36","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1210\/jc.2016-2046","article-title":"Cancer risks in patients treated with growth hormone in childhood: the SAGhE European Cohort Study","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071623270560900_B37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-11-0286","article-title":"Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study","volume":"165","author":"Child","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2020071623270560900_B38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant human growth hormone in children","volume":"95","author":"Bell","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071623270560900_B39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2010.02.028","article-title":"Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database)","volume":"157","author":"Wilton","year":"2010","journal-title":"J Pediatr"},{"issue":"3","key":"2020071623270560900_B40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000284358","article-title":"Analyses of treatment variables for patients with childhood craniopharyngioma--results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up","volume":"73","author":"M\u00fcller","year":"2010","journal-title":"Horm Res Paediatr"},{"issue":"9329","key":"2020071623270560900_B41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(02)09519-3","article-title":"Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study","volume":"360","author":"Swerdlow","year":"2002","journal-title":"Lancet"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/8\/2794\/25408139\/jc.2018-01205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/103\/8\/2794\/25408139\/jc.2018-01205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T12:22:25Z","timestamp":1594988545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/103\/8\/2794\/5046570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-01205","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,6,29]]}}}